Use of insulin-like growth factors I and II for inhibition of in

Details Use of insulin-like growth factors I and II for inhibition of in Use of insulin-like growth factors I and II for inhibition of in

1995-05-19

1998-01-27

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 8, 514 21, 604273, A61K 3736, A61K 3800, C07K 710

Patent

active

057122490

ABSTRACT:
The present invention relates to methods for using IGF as inhibitors of inflammatory response, ischemic injury, and organ rejection.

REFERENCES:
patent: 4738921 (1988-04-01), Belagaje et al.
patent: 4783524 (1988-11-01), Larsen et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4861757 (1989-08-01), Antoniades et al.
patent: 4929555 (1990-05-01), Cregg et al.
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5028531 (1991-07-01), Ueda et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5158875 (1992-10-01), Miller et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5206023 (1993-04-01), Hunzinker
patent: 5270300 (1993-12-01), Hunzinker
patent: 5273961 (1993-12-01), Clark
patent: 5294446 (1994-03-01), Schlameus et al.
patent: 5434134 (1995-07-01), Gluckman
Gluckman et al. Biochem Biophys Res. Comm., vol. 182, No. 2, Jan. 31, 1992, pp. 593-599.
Shosker et al. Transplantation vol. 49, 201-207, No. 1, Jan. 1990.
Matejka and Jennische, Kidney International, vol. 42, pp. 1113-1123, 1992.
Shoskes et al., "Ischemic injury induces altered MHC gene expression in kidney by an interferon-gamma-dependent pathway," Transplantation Proceedings 23(1):599-601 (1991).
Goes et al., "Insulin-Like Growth Factor-1 (IGF-1) Reduces Cytokine and MHC Induction After Acute Tubular Necrosis (ATN)," Journal of American Society of Nephrology, 27th Annual Meeting, October 26-29, 1994 (Sep. 1994, vol. 5, No. 3).
Miller, PNAS (USA) (1992) 89:11876.
Matejka, Kidney International (1992) 42:1113.
Gluckman, Biochem. Biophys. Res. Comm. (1992) 182:593.
Middleton, Annals of Rheumatic Diseases (1992) 51:440.
Moskowitz, J. of Rheumatology, supp. (1991) 27:147.
Dequeker Arthritis and Rheumatism (1993) 36:1702.
Hampton, J. of Biol. Chem. (1989) 264:19155.
Denko, J. of Rheumatology (1990) 17:1217.
Ding J. of Clin. Invest. (1993) 91:2281.
Rogachefsky, Ostearthritis and Cartilage, (1993) 1:105-114.
Cockfield, J. Immunol (1989) 142:1120.
Cregg, Mol. Cell. Biol. (1985) 5:3376.
Das, J. Bacteriol, (1984) 158:1165.
De Louvencourt, J. Bacteriol. (1983) 154:737.
Graham, J. Gen. Virol. (1977) 36:59.
Ito, J. Bacteriol. (1983) 153:163.
Kurtz, Mol. Cell. Biol. (1990) 23:243.
Mather, Biol. Reprod. (1980) 23:243.
Phillips, New Engl. J. Med. (1990) 302:371-380.
Reyes, Nature (1982) 297:598.
Roggenkamp, Mol. Gen Genet. (1986) 202:302.
Salacinski, Anal. Biochem. (1981) 117:136.
Shoskes, Transplantation (1990) 49:201.
Tilburn, Gene (1983) 26:205.
Urlaub, PNAS (USA) (1990) 77:4216.
Van den Berg, Bio/Technology (1990) 8:135.
Yelton, PNAS (USA) (1984) 1981:1470.
Kelly et al., EMBO J. (1985) 4:475-479.

Affiliated with

Also associated with

Rating

Use of insulin-like growth factors I and II for inhibition of in does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of insulin-like growth factors I and II for inhibition of in, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of insulin-like growth factors I and II for inhibition of in will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-342319